Few Differences Found in Outcomes With Various Venous Thromboembolism Prophylaxis Protocols
Researchers found that most instances of venous thromboembolism occurred while patients were receiving prophylaxis.
Researchers found that most instances of venous thromboembolism occurred while patients were receiving prophylaxis.
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
Risk of venous thromboembolism (VTE) may be higher in patients with cancer who receive chemotherapy.
Thromboprophylaxis with dalteparin is associated with a non-significant decreased risk of venous thromboembolism (VTE).
Among patients with active cancer, full-dose tinzaparin daily compared with warfarin did not significantly reduce the composite measure of recurrent VTE.
Prevalence of occult cancer is low among patients with first unprovoked venous thromboebolism (VTE).
The placement of an inferior vena cava filter is understudied in patients with cancer and clear guidelines do not exist.
Therapeutic anticoagulation is safe for treating venous thromboembolism in patients with cancer that has metastasized to the brain.
Recent research shows that enoxaparin effectively prevents VTE complications in advanced pancreatic cancer without decreasing efficacy of chemotherapy.